UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form 8-K

 

Current Report Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 11, 2006

 

 

Metabasis Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

 

000-50785

 

33-0753322

(State or other jurisdiction of
incorporation)

 

(Commission File Number)

 

(I.R.S. Employer
Identification No.)

 

 

 

 

 

11119 North Torrey Pines Road
La Jolla, California

 

92037

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (858) 587-2770

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 


 

Item 2.02               Results of Operations and Financial Condition.

 

On May 11, 2006, we announced financial results for the first quarter ended March 31, 2006 in the earnings release attached hereto as Exhibit 99.1 and incorporated herein by reference.

 

The information in this Item 2.02 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section.  The information in this Item 2.02 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.

 

Item 9.01               Financial Statements and Exhibits.

 

(d)           Exhibits.

 

99.1         Press release of Metabasis Therapeutics, Inc. dated May 11, 2006.

 

2


 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

METABASIS THERAPEUTICS, INC.

 

 

 

By:

/s/ John W. Beck 

 

 

 

John W. Beck

 

 

Senior Vice President of Finance, Chief
Financial Officer and Treasurer

 

 

 

Date: May 11, 2006

 

 

 

3


 

INDEX TO EXHIBITS

 

99.1

 

Press release of Metabasis Therapeutics, Inc. dated May 11, 2006.

 

4